Screening Process Failures for Hepatocellular Carcinoma

被引:30
|
作者
Singal, Amit G. [1 ,2 ,3 ,4 ]
Marrero, Jorge A. [1 ,2 ,3 ]
Yopp, Adam [3 ,5 ]
机构
[1] UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA
[2] Parkland Hlth Hosp Syst, Dallas, TX USA
[3] UT Southwestern Med Ctr, Dallas, TX USA
[4] Univ Texas Southwestern, Dept Clin Sci, Dallas, TX 75390 USA
[5] Univ Texas Southwestern, Dept Surg, Dallas, TX 75390 USA
关键词
NATURAL-HISTORY; GROWTH-RATE; SURVEILLANCE; CIRRHOSIS; EPIDEMIOLOGY; MANAGEMENT; SURVIVAL; RATES; CARE;
D O I
10.6004/jnccn.2014.0039
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
More than 60% of patients with hepatocellular carcinoma (HCC) are diagnosed at a late stage, suggesting potential breakdowns in the HCC screening process. Understanding which steps in the screening process are not being performed is essential for designing effective interventions. To characterize HCC screening process failures, a retrospective cohort study of patients with cirrhosis diagnosed with HCC at a large urban safety-net hospital was conducted between 2005 and 2012. Screening process failures during the year before HCC diagnosis were characterized into 3 categories: absence of surveillance, failure of detection, and delayed follow-up. Univariate and multivariate analyses were performed to identify predictors of screening process failures. A total of 185 patients with cirrhosis and HCC were identified, of whom 91 (49%) were diagnosed at an early stage (Barcelona Clinic Liver Cancer system stage A). Only 16 (8.6%) patients successfully completed the screening process. Absence of surveillance was the most common screening process failure, found in 75.7% of all patients, and was associated with trends toward lower rates of early tumor detection (odds ratio, 0.51; 95% CI, 0.23-1.09) and worse overall survival (hazard ratio, 0.79; 95% CI, 0.49-1.25). Failure of detection and delayed follow-up were found in 11.4% and 2.7% of patients, respectively.
引用
收藏
页码:375 / 382
页数:8
相关论文
共 50 条
  • [41] Issues in screening and surveillance for hepatocellular carcinoma
    Di Bisceglie, AM
    [J]. GASTROENTEROLOGY, 2004, 127 (05) : S104 - S107
  • [42] Screening for Hepatocellular Carcinoma: What Is Missing?
    Mehta, Neil J.
    Celik, Aygul Dogan
    Peters, Marion G.
    [J]. HEPATOLOGY COMMUNICATIONS, 2017, 1 (01) : 18 - 22
  • [43] Screening Parameters of Hepatocellular carcinoma to the Test
    Schmid, S.
    Hager, M.
    Mueller-Schilling, M.
    Salzberger, B.
    Kirchner, G.
    [J]. INTERNIST, 2013, 54 : 32 - 32
  • [44] EVALUATION OF POPULATION SCREENING FOR HEPATOCELLULAR CARCINOMA
    汤钊猷
    杨秉辉
    唐辰龙
    余业勤
    林芷英
    翁惠知
    [J]. CHINESE MEDICAL JOURNAL., 1980, (11)
  • [45] Is MRI recommendable for screening of hepatocellular carcinoma?
    Rabe, C
    Caselmann, WH
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (23) : 1275 - 1276
  • [46] The Screening of Volatile Markers for Hepatocellular Carcinoma
    Qin, Tao
    Liu, Hu
    Song, Qi
    Song, Geng
    Wang, Hong-zhi
    Pan, Yue-yin
    Xiong, Fu-xing
    Gu, Kang-sheng
    Sun, Guo-ping
    Chen, Zhen-dong
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (09) : 2247 - 2253
  • [47] Screening for Hepatocellular Carcinoma: Where Is the Inconsistency?
    Braillon, Alain
    [J]. AMERICAN JOURNAL OF MEDICINE, 2015, 128 (03): : E25 - E25
  • [48] Screening for hepatocellular carcinoma in cirrhotic patients
    Beaugrand, M
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2000, 24 (5BIS): : B92 - B94
  • [49] Screening for hepatocellular carcinoma by Egyptian physicians
    Hassany, Sahar M.
    Moustafa, Ehab F. Abdou
    El Taher, Mohamed
    Abdeltwab, Afaf Adel
    Blum, Hubert E.
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 7 (09) : 161 - 171
  • [50] SCREENING METHODS FOR HEPATOCELLULAR-CARCINOMA
    EZAKI, T
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1991, 156 (04) : 869 - 869